AbbVie sees the combined sales of Rinvoq, Skyrizi eclipse the top sales of Humira (NYSE:ABBV)

Abbott and Abbvie sign at their headquarters in Abbott Park, IL, USA.

Photo JHVE

Although AbbVie’s blockbuster treatment Humira (adalimumab) will watch this year’s biosimilar contestThe company hopes that Rinvoq (upadacitinib) and Skyrizi (risankizumab) will eventually have a combined peak sales higher than during Humira’s peak.

Speaking at JP Morgan Healthcare


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button